Mitral valve (MV) repair is preferred over replacement in clinical guidelines and is an important determinant of the indication for surgery in degenerative mitral regurgitation. However, the level of evidence supporting current recommendations is low, and recent data cast doubts on its validity in the current era. Accordingly, the aim of the present study was to analyze very long-term outcome after MV repair and replacement for degenerative mitral regurgitation with a flail leaflet.
M itral regurgitation (MR) is the most prevalent valvular disease in the Western world.
1,2 Degenerative MR with mitral prolapse commonly requires surgical correction, 3 which alleviates grim prognosis of severe regurgitation [4] [5] [6] and restores normal life expectancy. 7, 8 Mitral valve (MV) repair is preferred to MV replacement and has been increasingly performed on the basis of comparative studies conducted in the 1980s showing repair superiority for operative mortality, [9] [10] [11] left ventricular function, 12 valve-related complications, and long-term survival. [13] [14] [15] Accordingly, American and European guidelines recommend MV repair as a Class I indication (when it is expected to be durable) and more recently have also recommended that patients with severe degenerative MR be referred to centers with expertise in valve repair. 7, 8 Despite these recommendations, foundational evidence is rather low 7, 8 and derived largely from nonrandomized, single-center studies using crude statistical adjustments to control for differences in baseline characteristics between patient groups. [16] [17] [18] [19] [20] Moreover, the causes of MR were nonuniform and may have been biased against outcome after valve replacement when repair was not feasible. In addition, these studies were conducted in an era when operative mortality was still high and chordal sparing was not routine, potentially adversely affecting left ventricular geometry and function. 12 Conversely, in the current era, surgical risk has decreased markedly, 21 and preservation techniques during MV replacement, protective of left ventricular geometry and function, have markedly improved. 22 Recent data comparing MV repair and replacement failed to demonstrate superiority of repair in specific subgroups such as elderly patients, 17, 23 women, 24 patients with endocarditis, 25 or those with ischemic MR. 26 They all have raised a contemporary challenge on valve repair superiority. If MV replacement is noninferior to MV repair, consequences would be wide-ranging in terms of treatment algorithms centered on valve reparability and in terms of valve repair as a quality measure for valve centers. Furthermore, in the development of percutaneous techniques, percutaneous repair could be replaced by an easier and standardized percutaneous valve replacement.
For the purpose of this indispensable repair versus replacement comparison, to promptly obtain data on longterm outcome, we used the large multicenter MIDA (Mitral Regurgitation International Database) registry, which was designed to study patients with uniformly classified degenerative MR. Using state-of-the-art statistical methods to balance risk factors between clinical cohorts, we tested the null hypothesis that valve repair and replacement provide similar short-and long-term outcomes.
METHODS

Study Design
All participating medical centers provided ethics and institutional review board approval. The study was conducted in accordance with institutional policies, national legal requirements, and the revised Helsinki Declaration. The MIDA registry systematically merged the consecutive experience with degenerative MR of 6 tertiary centers: 2 in France (university hospitals in Amiens and Marseille), 2 in Italy (university hospitals in Bologna and Modena), 1 in Belgium (university hospital in Brussels), and 1 in the United States (Mayo Clinic, Rochester, MN). Institutional review board authorizations were obtained before the study was started. The study was conducted in accordance with the institutional policies and national legal requirements prevailing at the time of patient recruitment.
Patient Population
Patients were enrolled in the MIDA registry if they had degenerative MR with a flail leaflet detected by a 2-dimensional transthoracic echocardiography between January 1, 1980, and December 31, 2005 , and none of the following: ischemic MR; significant concomitant aortic valve disease, congenital heart diseases, mitral stenosis, and prior valve surgery.
The MIDA registry currently includes 2472 patients. From this initial cohort, 1922 patients who underwent either MV repair (n=1709) or MV replacement (n=213) were included in the present analysis. Patients only treated medically (n=538), <18 years of age (n=2), or with incomplete data sets (n=10) were not considered for inclusion.
Surgical Procedure
Surgical methods to repair the MV evolved over the 35-year study period. In the first half of the study, posterior leaflet prolapses were mostly corrected by resection and suture repair of
Clinical Perspective
What Is New?
• We found that closely matched patients undergoing mitral valve (MV) repair for degenerative mitral regurgitation with a flail leaflet have a lower operative mortality, a better long-term survival, and a similar risk of reoperation compared with patients undergoing MV replacement.
• We also found that the association between MV repair and improved survival appears to be sustained 20 years after surgery and is observed in all the prespecified age subgroups.
• Last, we observed that MV repair is associated with a lower risk of valve-related complications than MV replacement.
What Are the Clinical Implications?
• Our findings suggest that MV repair should be preferred over MV replacement for patients with degenerative mitral regurgitation and a flail leaflet.
• Whenever possible, patients should be referred to surgical centers experienced in performing MV repair.
the involved portion of the posterior leaflet, whereas anterior leaflet prolapses were corrected by chordal shortening, chordal transfer, or commissural annuloplasty. In recent years, fewer and smaller resections of the posterior leaflet were used to correct posterior leaflet prolapses. In both anterior and posterior leaflet prolapses, insertion of artificial Gore-Tex neochordae to resuspend the prolapsing segments progressively became the standard surgical approach. Throughout the study period, leaflet surgery was always supplemented by some form of remodeling annuloplasty: with semirigid or rigid rings in the European centers and flexible posterior annuloplasty bands at the Mayo Clinic.
Echocardiography
Transthoracic echocardiograms were performed in routine clinical practice as previously described. 6, 27 The severity of MR was assessed semiquantitatively on a scale from 1 to 4 by Doppler echocardiography. 28 Diagnosis of flail leaflet was based on failure of leaflet coaptation with rapid systolic movement of the involved leaflet tip within the left atrium.
Outcomes
The primary end point was all-cause mortality, and secondary end points were operative mortality and valve-related complications (reoperations, thromboembolism, major bleeding, infective endocarditis). Definitions of these complications have been published previously.
3,4
Follow-Up
Events were collected through direct review of clinical data, patient interview, and follow-up letters and questionnaires. Causes of death were adjudicated by review of death certificates, physician and hospital notes, and autopsy reports.
Statistical Analysis
All statistical analyses were performed with SPSS 22, NCSS 2007, or R version 3.0.2 (inverse probability of treatment weight [IPW] 1.0-10) software. Continuous variables were expressed as mean±SD and compared by use of 2-sided Student t tests, and categorical variables were summarized as frequency percentages and analyzed by χ 2 tests. Long-term survival was computed with the Kaplan-Meier method and compared by use of the log-rank χ 2 test. Cox proportional hazards regression models were used to determine the association between MV repair and outcomes. Subgroup analyses were conducted with the use of tests for interactions in the Cox regression model. A significance level of 0.05 was assumed for all statistical tests.
Propensity Score Matching
Variables associated with survival as indicated in univariate Cox models were used for calculating propensity scores. 29, 30 The propensity for MV repair was then estimated with a logistic regression model, with the response variable being surgery MV repair (yes/no). The covariables used to build the propensity score were age, sex, diabetes mellitus, smoking habits, dyslipidemia, arterial hypertension, previous surgery, history of endocarditis, Charlson sum, leaflet involvement, New York Heart Association functional class, left ventricular ejection fraction, concomitant coronary artery bypass graft surgery, atrial fibrillation, and pulmonary hypertension. A single propensity score was generated for each patient and used to select pairs of patients with matched propensity scores in the 2 surgery groups (2:1 match) within a caliper of 0.19 SD of the propensity score. For this purpose, we used the greedy, nearestneighbor matching algorithm included in the psmatch routine. Bias reduction and balance between the groups of patients with MV repair and MV replacement were assessed with standardized differences of covariates. An absolute standardized difference <10% indicates a small imbalance.
IPW
Using the same baseline characteristics for the propensity score calculation allowed case-weight estimation with a logistic regression model to predict the inverse probability of having a MV repair. The case weights balanced the cohorts for an IPW analysis that included all patients with available data. Weighted t tests and weighted χ 2 tests were used in the IPW analyses to compare continuous or categorical variables in the surgery groups. Standardized differences were calculated to compare baseline characteristics in the surgery groups for the original and the inverse probability-of-treatment weighting-adjusted cohort. 31 Cox proportional hazard regression models were adjusted for inverse probability weights 32, 33 to determine the impact of the type of surgery on survival. Survival models were further stratified by age groups: <65, 65 to 74, and >75 years. To account for variation in medical centers, Cox models were used with center as clusters in the models. 34 The proportional hazards assumption in the Cox models was assessed with Schoenfeld residuals; the model fit was evaluated with Martingale and Cox-Snell residuals. A 2-sided value of P<0.05 was considered statistically significant. Last, subgroup analyses were conducted with the use of for interaction tests in the Cox regression model.
RESULTS
Baseline Characteristics
Baseline characteristics of the overall population and of the subset of the propensity score-matched population are shown in Table 1 . Although some baseline differences were noted between the MV repair and replacement groups before propensity score matching or IPW adjustments, the 2 groups were well balanced after matching by propensity score and after IPW adjustment, and absolute standardized differences were usually <10%, indicating adequate match ( Figure I in the online-only Data Supplement).
Operative Mortality
Operative mortality (defined as a death occurring within 30 days from surgery or during the same hospitalization) occurred overall in 33 patients (1.7%) and was lower after MV repair (1.3%, 23 of 1709) than after MV replacement (4.7%, 10 of 213; P<0.001). In the propensity-matched cohort, operative mortality was also lower in the MV repair (0.2%, 1 of 410) than in the MV replacement (4.4%, 9 of 205; P<0.001) group.
Long-Term Survival
During a mean follow-up of 9.4 years (range, 4.4-18.1 years), a total of 552 deaths were observed, of which 207 were of cardiovascular origin. Overall survival of the total population was 75% (95% confidence interval [CI], 73-77) at 10 years and 43% (95% CI, 37-48) at 20 years.
Ten-and 20-year overall survival of the unmatched cohort was also significantly better after MV repair (77% Figure 1A) . The multivariable Cox model for the overall cohort adjusted for age, left ventricular ejection fraction, Charlson index, New York Heart Association class III to IV, atrial fibrillation, concomitant bypass surgery, and previous heart surgery confirmed again that MV repair was associated with higher survival (Table 2) .
Propensity score matching of the MV repair and replacement groups yielded 615 patients (2:1 matching). Direct comparison of survival in the matched groups Figure 1B ). With the use of the IPW Cox model, MV repair was again associated with better survival (Table 2) . Twenty-year IPW-adjusted survival was significantly better after MV repair than after MV replacement (47% [95% CI, 29-59] versus 31% [95% CI, 9-65; P<0.001; Figure 1C ).
Impact of MV Repair on Long-Term Survival in Different Age Groups
To confirm that the survival advantages associated with MV repair were independent of age, we separated the study population into 3 prespecified age groups. Postoperative survival was better after MV repair than after MV replacement in each of these age subgroups ( Figure 2 ) in both the overall and propensity-matched populations. In patients ≥75 years of age, the survival advantage brought about by MV repair was initially modest but increased over time and was overall significant. Multivariable Cox models for each age subgroup adjusted for the same parameters as in the overall population confirmed that MV repair was associated with better survival regardless of age. Similar results were obtained with IPW Cox models ( Table 2) .
Subgroup Analyses of Long-Term Survival
The survival benefit associated with MV repair was consistently observed in the following subgroups ( Figure 3 
Freedom From Reoperation
During follow-up, 95 MV reoperations were observed, of which 78 were indicated for a recurrent significant MR (69 in the MV repair group), 10 for infective endocarditis, 3 for thromboembolism, and 4 for mitral stenosis. Figure 4 shows MV reoperation-free survival among the MV repair and replacement groups.
Freedom From Recurrent MR
Data on recurrent MR after MV repair were available for 1480 patients. During follow-up, 115 of these patients Graphs on the right show survival in the IPW-adjusted cohort. Numbers at bottom indicate patients at risk.
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Freedom From Valve-Related Complications
During the follow-up period, 152 embolic events (transient ischemic attacks or strokes) and 47 gastrointestinal bleeding events (all in patients receiving warfarin) occurred. Sixteen patients developed infective endocarditis. Twenty-year freedom from valverelated events (ie, stroke, bleeding, and endocarditis) was 83% (95% CI, 80-86) after MV repair and 50% (95% CI, 32-66; P<0.001) after MV replacement (Figure 5) . Similar results were obtained in the matched and IPW-adjusted cohorts. Twenty-year freedom from endocarditis was also better after MV repair than after MV replacement ( Figure IV in the online-only Data Supplement).
DISCUSSION
The MIDA registry is a prospective, noninterventional, multicenter, international registry that includes all consecutive patients diagnosed in routine practice with degenerative MR with a flail leaflet at 6 tertiary referral centers from Europe and the United States. 6, 27 To the best of our knowledge, it is the largest registry in the world specifically designed to investigate pure MV regurgitation with a flail mitral leaflet. By enrolling consecutive patients in both Europe and the United States, it is also the only one with results that are potentially applicable to patients from both continents. The present analysis indicates that closely matched patients undergoing MV repair for degenerative MR with a flail leaflet have a lower operative mortality, a better long-term survival (total mortality decrement of ≈50%), and a similar risk of reoperation compared with patients undergoing MV replacement. Long term, the results are congruent by all methods used (direct comparison, propensity score matching, inverse probability weighing). Furthermore, the survival benefit associated with MV repair appears to be sustained 20 years after surgery and is observed in all the prespecified age subgroups.
Current American Heart Association/American College of Cardiology and European Society of Cardiology guidelines strongly recommend MV repair as the preferred surgical method to treat severe degenerative MR. 7, 8 Although the evidence supporting these recommendations is derived largely from single-center, observational series, the observed superiority of MV repair is so strong that the guidelines consider a low likelihood of achieving a durable repair as a legitimate reason to refer patients to centers with significant experience in MV repair or to delay surgery until the disease is more advanced. 7, 8 To date, no randomized trials comparing MV repair and replacement have been conducted in patients with degenerative MR. 7, 8 Although the results of the Cardiothoracic Surgical Trials Network trial failed to reveal an outcome benefit of MV repair over MV replacement in patients with ischemic MR, raising more than legitimate concerns about the objective superiority of MV repair, 26 this condition is a disease of the ventricle, and therefore, valve repair is likely not as influential. Several retrospective studies have reported better outcomes after MV repair than after MV replace- ment, 20, 24, 35, 36 whereas others failed to demonstrate any superiority of one approach over the other. 17, [23] [24] [25] [26] These diverging results are most likely related to the retrospective nature of these studies, the small number of patients included, the mixing of patients with MR of various causes, the potential for referral biases in singlecenter studies, and the lack of appropriate statistical analyses to compensate for the absence of randomization. Our study is thus unique not only because of its large sample size and its multicenter design but also because it exclusively concentrated on the outcome of patients with degenerative MR with a flail leaflet. We also used state-of-the-art statistical methods to minimize the consequences of the lack of randomization, taking advantage of our large sample size and using both propensity score matching and IPW to obtain comparable treatment cohorts. IPW allows working with the entire cohort by weighting patients according to mismatched characteristics and thereby avoiding loss of power. Using this approach, we obtained well-balanced treatment groups, allowing comparison of long-term outcomes in both treatment arms and eventually confirming the beneficial effects associated with MV repair. The results are self-explanatory and strongly support the use of MV repair to treat patients with severe degenerative MR with a flail leaflet.
The present study also shows that MV repair can be undertaken with low operative mortality and morbidity and good long-term survival. In addition, it shows that the survival advantage resulting from MV repair over replacement is independent of age. However, in patients ≥75 years old, the survival advantage associated with MV repair increased progressively after surgery, suggesting that patients symptomatic but with short life expectancy for other reasons may also be treated by valve replacement. These results differ somewhat from those of previous investigators who did not observe a similar time lag in the benefits from MV repair, possibly because patients with different baseline characteristics were enrolled. 20 The present study shows that the survival advantage associated with MV repair is independent of the year of surgery, thus suggesting little effect of learning curve, and of the presence or absence of guideline triggers, which suggests that, even in the sickest patients, MV repair outperforms MV replacement despite longer bypass and cross-clamp times.
Study Limitations
This study has some limitations that should be acknowledged. First, despite the prospective nature of the MIDA registry, the completeness of our follow-up data, and the use of sophisticated statistical methods to reduce biases, our patients were not randomized between MV repair and replacement, and the number of patients undergoing replacement was significantly smaller. Accordingly, we cannot exclude the possibility that unaccounted confounding factors contributed to our results. A prospective, randomized trial would undoubtedly provide a more definite demonstration of the superiority of mitral reconstruction. However, at this point in the history of mitral surgery, the present study provides solid scientific evidence while waiting for such a trial to be performed. Second, the time frame of our study was very long (35 years), which implies that the surgical techniques and the criteria to quantify MR severity have changed over the years. Although this allowed long-term results to be reported, it also forced us to lump together outcomes of patients with different baseline characteristics or treated by different surgical techniques. The observation that MV repair outperformed MV replacement independently of the year of surgery is quite reassuring in this regard. It indeed suggests that the good results of MV repair are largely independent of the surgical techniques used as long as a competent MV is obtained at the end of surgery. The MIDA registry involves mostly high-volume surgical centers with expertise in MV evaluation and repair. Whether centers less specialized or with lower surgical volume may provide similar outcome cannot be ascertained. Although at present it is essential to factor into practice the benefits of mitral repair in specialized centers in all subsets of patients with flail leaflets, it will be important in the future to verify with collaborative studies that similar benefits can be obtained in less specialized centers.
Conclusions
Data from the international MIDA registry demonstrate that in patients with severe degenerative MR with a flail leaflet, MV repair is associated with lower operative mortality and better long-term survival compared with MV replacement. The benefits of MV repair were confirmed in every age subgroup and independently from the era of the operation. These data support current recommendations and substantiate the contention that, when feasible, MV repair should be the preferred treatment of severe degenerative MR and should remain a central condition of treatment algorithms and quality measure of valve centers. 37 
